

RECEIVED

APR 11 2002

SHEET 1 of 8

Form PTO-1449 (Modified)

FEB 28 2002

U.S. Department of Commerce  
Patent and Trademark Office

TECH CENTER 1600/2900

Applicant No.  
27611/36927Serial No.  
09/995,403

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Alkan-Onyuksel et al.Filing Date  
11/27/01Group  
1614

## U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
<i>lu</i>	A1	4,920,016	04/24/90	Allen, T.M. et al.	424	450	
	A2	5,514,670	05/07/96	Friedman, D. et al.	514	2	

## FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
<i>lu</i>	B1	WO 97/35561	10/02/97	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

<i>lu</i>	C1	Alessandrini, F. et al., "Vasoactive Intestinal Peptide Enhances Lung Preservation," <i>Transplantation</i> , 56(4):964-973 (October, 1993).
	C2	Allen, T.M. et al., "Large Unilamellar Liposomes with Low Uptake into the Reticuloendothelial System," <i>Federation European Biochemical Societies</i> , 223(1):42-46 (October, 1987)
	C4	Allen, T.M. et al., "Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo," <i>Biochimica et Biophysica Acta</i> , 1066:29-36 (1991).
	C4	Almgren, M. et al., "Self-aggregation and phase behavior of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymers in aqueous solution," <i>Colloid Polym Sci.</i> , 273:2-15 (1995).
	C5	Artwohl, J.F. et al., "Initial Characterization of Hamsters with Spontaneous Hypertension," <i>FASEB J.</i> , 10:A628 (1996).
<i>u</i>	C6	Avidor, R. et al., "VIP-mRNA is increased in hypertensive rats," <i>Brain Research</i> , 503:304-307 (1989).

EXAMINER

*kuh*

DATE CONSIDERED

7/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

RECEIVED

APR 11 2002

SHEET 2 of 8

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
1600/2900Serial No.  
09/995,403Applicant  
Alkan-Onyuksel et al.Filing Date  
11/27/01Group  
1614

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

W	C7	Bangham, A.D. <i>et al.</i> , "Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids," <i>J. Mol. Biol.</i> , 13:238-252 (1965).
	C8	Bedu-Addo, F.K. <i>et al.</i> , "Interaction of Polyethyleneglycol-Phospholipid Conjugates with Cholesterol-Phosphatidylcholine Mixtures: Sterically Stabilized Liposome Formulations," <i>Pharmaceutical Research</i> , 13(5):718-724 (1996)
	C9	Berisha, H. <i>et al.</i> , "Vasoactive intestinal peptide prevents lung injury due to xanthine oxidase," <i>Am. J. Physiol.</i> , 259:L151-L155 (1990).
	C10	Bodanszky, M. <i>et al.</i> , "A Preferred Conformation in the Vasoactive Intestinal Peptide (VIP). Molecular Architecture of Gastrointestinal Hormones," <i>Bioorganic Chemistry</i> , 3:133-140 (1974).
	C11	Bolin, D.R. <i>et al.</i> , "Design and Development of a Vasoactive Intestinal Peptide Analog as a Novel Therapeutic for Bronchial Asthma," <i>Biopolymers, (Peptide Science)</i> 37:57-66 (1995).
	C12	Carey, M.C. <i>et al.</i> , "Micelle Formation by Bile Salts," <i>Arch Inter. Med.</i> , 130:506-527 (October, 1972).
	C13	Chiba, K. <i>et al.</i> , "Interaction Between Lipids and Bovine Brain Calmodulin: Lysophosphatidylcholine-Induced Conformation Change," <i>Life Science</i> , 47:953-960 (1990).
	C14	Damrongchai, N. <i>et al.</i> , "Calcium Responsive Two-Dimensional Molecular Assembling of Lipid-Conjugated Calmodulin," <i>Bioconjugate Chem.</i> , 6:264-268 (1995).
	C15	DeGrado, W.F. <i>et al.</i> , "Induction of Peptide Conformation at Apolar/Water Interfaces. 1. A Study with Model Peptides of Defined Hydrophobic Periodicity," <i>J. Am. Chem. Soc.</i> , 107:7684-7689 (1985).
	C16	Fournier, A. <i>et al.</i> , "Synthesis, Conformational Studies and Biological Activities of VIP and Related Fragments," <i>Peptides</i> 5:169-177 (1984).
✓	C17	Frase, L.L. <i>et al.</i> , "Cardiovascular Effects of Vasoactive Intestinal Peptide in Healthy Subjects," <i>Am. J. Cardio.</i> , 60:1356-1361 (1987).

EXAMINER

Kish

DATE CONSIDERED

7/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APR 1 2002

SHEET 3 of 8

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

TECH CENTER 1600/2900

Atty. Docket No.  
27611/36927Serial No.  
09/995,403Applicant  
Alkan-Onyuksel et al.Filing Date  
11/27/01Group  
1614

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

1	C18	Fry, D.C. et al., "Solution Structure of an Analogue of Vasoactive Intestinal Peptide As Determined by Two-Dimensional NMR and Circular Dichroism Spectroscopies and Constrained Molecular Dynamics," <i>Biochemistry</i> , 28:2399-2409 (1989).
	C19	Gabizon, A. et al., "Liposome Formulations with Prolonged Circulation Time in Blood and Enhanced Uptake by Tumors," <i>Proc. Natl. Acad. Sci. (USA)</i> , 85:6949-6953 (September, 1988).
	C20	Ghosh, et al., "Effect of Surface Modification with Glycolipids and Polysaccharides on <i>In Vivo</i> Fate of Liposomes," <i>Stealth Liposomes</i> 13-24 (1995)
	C21	Gozes, I. et al., "VIP: Molecular Biology and Neurobiological Function," <i>Molecular Neurobiology</i> , 3:201-236 (1989).
	C22	Gozes, I. et al., "Stearyl-Norleucine-Vasoactive Intestinal Peptide (VIP): A Novel VIP Analog for Noninvasive Impotence Treatment," <i>Endocrinology</i> , 134(5):2121-2125 (1994).
	C23	Gozes, I. et al., "Superactive Lipophilic Peptides Discriminate Multiple Vasoactive Intestinal Peptide Receptors <sup>1</sup> ," <i>J. Pharmacology Experimental Therapeutics</i> , 273:161-167 (1996).
	C24	Haghjoo, K. et al., "Solution Structure of Vasoactive Intestinal Polypeptide (11-28)-NH <sub>2</sub> , a Fragment with Analgesic Properties," <i>Peptide Research</i> , 9(6):327-331 (1996).
	C25	Hamed, M.M. et al., "Behavior of Amphipathic Helices on Analysis via Matrix Methods, with Application to Glucagon, Secretin, and Vasoactive Intestinal Peptide," <i>Biopolymers</i> , 22:1003-1021 (1983).
	C26	Hirata, Y. et al., "Functional Receptors For Vasoactive Intestinal Peptide In Cultured Vascular Smooth Muscle Cells From Rat Aorta," <i>Biochemical Biophysical Research Communications</i> , 132(3):1079-1087 (November, 1985).
2	C27	Hjelm, R.P. Jr. et al., "Organization of Phosphatidylcholine and Bile Salt in Rodlike Mixed Micelles," <i>J. Phys. Chem.</i> , 96(21):8653-8661 (1992).


EXAMINER

Kuh

DATE CONSIDERED

7/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27611/36927Serial  
09/99Applicant  
Alkan-Onyuksel et al.Filing Date  
11/27/01Group  
1614

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

2001/2/00

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

h	C28	Hökfelt, T., "Neuropeptide in Perspective: The Last Ten Years," <i>Neuron</i> , 7:867-879 (1991).
	C29	Houbre, D. <i>et al.</i> , "The Interactions of the Brain-specific Calmodulin-binding Protein Kinase C Substrate, Neuromodulin (GAP 43), with Membrane Phospholipids," <i>Journal Biological Chemistry</i> , 266(11):7121-7131 (April, 1991).
	C30	Kaiser, E.T. <i>et al.</i> , "Peptides with Affinity for Membranes," <i>Ann. Rev. Biophys. Biophysical Chem.</i> , 16:561-581 (1987).
	C31	Klibanov, A.L. <i>et al.</i> , "Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes," <i>FEBS Lett.</i> , 268(1):235-237 (July, 1990).
	C32	Klibanov, A.L. <i>et al.</i> , "Activity of amphipathic poly(ethylene glycol) 5000 tp prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target," <i>Biochimica Biophysica Acta</i> , 1062:142-148 (1991).
	C33	Krejs, G.J., "Effect of Vasoactive Intestinal Peptide in Man," <i>Am. N.Y. Acad. Sci.</i> , 527:501-507 (1988).
	C34	Lasic, D. <i>et al.</i> , <i>Stealth Liposomes</i> , Lasic, D. <i>et al.</i> , (Eds.), CRC Press, Inc., Boca Raton, FL, pp. 1-289 (1995).
	C35	Litzinger, D.C. <i>et al.</i> , "Effect of Liposome Size on the Circulation Time and Intraorgan Distribution of Amphipathic Poly(ethylene glycol)-Containing Liposomes," <i>Biochimica et Biophysica Acta</i> , 1190:99-107 (1994).
	C36	Lutz, E.M. <i>et al.</i> , "The VIP <sub>2</sub> receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide," <i>FEBS Lett</i> , 334(1):3-8 (November, 1993).
✓	C37	Malhotra, R.K. <i>et al.</i> , "Vasoactive Intestinal Polypeptide and Muscarine Mobilize Intracellular Ca <sup>2+</sup> through Breakdown of Phosphoinositides to Induce Catecholamine Secretion," <i>Journal of Biological Chemistry</i> , 263(5):2123-2126 (1988).

EXAMINER

Kush

DATE CONSIDERED

7/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27611/36927Serial No.  
09/995,403Applicant  
Alkan-Onyuksel et al.Filing Date  
11/27/01Group  
1614

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

lu	C38	Maruyama, K. <i>et al.</i> , "Effect of Molecular Weight in Amphipathic Polyethyleneglycol on Prolonging the Circulation Time of Large Unilamellar Liposomes," <i>Chem. Pharm. Bull.</i> , 39(6):1620-1622 (1991).
	C39	McIntosh, et al., "Measurement of the Range and Magnitude of the Repulsive Pressure Between PEG-Coated Liposomes," <i>Stealth Liposomes</i> pp. 63-71 (1990).
	C40	Morice, A. <i>et al.</i> , "Vasoactive Intestinal Peptide Causes Bronchodilatation and Protects Against Histamine-Induced Bronchoconstriction in Asthmatic Subjects," <i>Lancet</i> , 262(8361):1225-1227 (November, 1983).
	C41	Muller, J. <i>et al.</i> , "VIP as a Cell-Growth and Differentiation Neuromodulator Role in Neurodevelopment," <i>Molecular Neurobiology</i> , 10:115-134 (1995).
	C42	Muranushi, N. <i>et al.</i> , "Effect Of Fatty Acids And Monoglycerides On Permeability Of Lipid Bilayer," <i>Chemistry and Physics of Lipids</i> , 28:269-279 (1981).
	C43	Musso, G.F. <i>et al.</i> , "Development of Helix-Based Vasoactive Intestinal Peptide Analogues: Identification of Residues Required for Receptor Interaction," <i>Biochemistry</i> , 27:8174-8181 (1988).
	C44	Nivaggioli, T. <i>et al.</i> , "Fluorescence Probe Studies of Pluronic Copolymer Solutions as a Function of Temperature," <i>Langmuir</i> , 11(3):730-737 (1995).
	C45	Noda, Y. <i>et al.</i> , "Partitioning of Vasoactive Intestinal Polypeptide into Lipid Bilayers," <i>Biochimica et Biophysica Acta</i> , 1191:324-330 (1994).
	C46	Nucci, M.L. <i>et al.</i> , "The Therapeutic Value of Poly(ethylene glycol)-Modified Proteins," <i>Advanced Drug Delivery Reviews</i> , 6:133-151 (1991).
	C47	Ollerenshaw, S. <i>et al.</i> , "Absence of Immunoreactive Vasoactive Intestinal Polypeptide in Tissue from the Lungs of Patients with Asthma," <i>New England Journal of Medicine</i> , 320:1244-1248 (May, 1989).
	C48	Omary, M.B. <i>et al.</i> , "Identification of Nuclear Receptors for VIP on a Human Colonic Adenocarcinoma Cell Line," <i>Science</i> , 238:1578-1581 (1987).
u	C49	Paul, S., "Vasoactive Intestinal Peptide: Its Interactions with Calmodulin and Catalytic Antibodies," <i>Neurochem. Int.</i> , 23(3):197-214 (1993).

EXAMINER

ku

DATE CONSIDERED

7/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED RECEIVED

MAR 05 2002  
APR 11 2002TECH CENTER 1600/2800  
TECH CENTER 1600/2800

FEB 28 2002

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27611/36927Serial No.  
09/995,400Applicant  
Alkan-Onyuksel et al.Filing Date  
11/27/01Group  
1614

SHEET 6 of 8

RECEIVED  
APR 11 2002  
TECH CENTER 1600/2910

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

W	C50	Paul, S. <i>et al.</i> , "Regulatory Aspects of the Vasoactive Intestinal Peptide Receptor in Lung," <i>Ann. N.Y. Acad. Sci.</i> , 527:282-295 (1988).
	C51	Raud, J., "Intravital Microscopic Studies on Acute Mast Cell-Dependent Inflammation," <i>Acta Physiologica Scandinavica Supplementum</i> 578:1-58 (1989).
	C52	Robinson, R.M. <i>et al.</i> , "Lipid-Induced Conformational Changes in Glucagon, Secretin, and Vasoactive Intestinal Peptide," <i>Biopolymers</i> , 21(6):1217-1228 (June 1982).
	C53	Rorstad, O.P. <i>et al.</i> , "Selectivity for Binding of Peptide Analogs to Vascular Receptors for Vasoactive Intestinal Peptide," <i>Molecular Pharmacology</i> , 37:971-977 (1990).
	C54	Rubinstein, I. <i>et al.</i> , "Tissue Angiotensin I-Converting Enzyme Activity in Spontaneously Hypertensive Hamsters," <i>Biochemical and Biophysical Research Communications</i> , 183(3):1117-1123 (March, 1992).
	C55	Said, S.I., "Vasoactive Intestinal Polypeptide (VIP): Current Status," <i>Peptides</i> , 5:143-150 (1984).
	C56	Said, S.I., "Vasoactive Intestinal Polypeptide: Biological Role in health and Disease," <i>Trends Endocrinology Metab.</i> , 2(3):107-112 (1991).
	C57	Said, S.I., "Vasoactive Intestinal Peptide (VIP) and Related Peptides as Anti-Asthma and Anti-Inflammatory Agents," <i>Biomedical Research</i> , 13(Supplement 2):257-262 (1992).
	C58	Saletu, B. <i>et al.</i> , "Comparative Bioavailability Studies with a New Mixed-micelles Solution of Diazepam Utilizing Radioreceptor Assay, Psychometry and EEG Brain Mapping," <i>International Clinical Psychopharmacology</i> , 3:287-323 (1988).
	C59	Sansom, .S.P., "The Biophysics of Peptide Models of Ion Channels," <i>Prog. Biophys. Molec. Biol.</i> , 55:139-235 (1991).
	C60	Séjourné, F. <i>et al.</i> , "Development of a Novel Bioactive Formulation of Vasoactive Intestinal Peptide in Sterically Stabilized Liposomes," <i>Pharmaceutical Research</i> , 14(3):362-365 (1997).

EXAMINER

ksh

DATE CONSIDERED

7/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APR 1 2002

TECH CENTER 1600/2800 EET 7 of 8

Form PTO-1449 (Modified)

FEB 28 2002

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27611/36927Serial No.  
09/995,403Applicant  
Alkan-Onyuksel et al.Filing Date  
11/27/01Group  
1614

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

lu	C61	Shiraga, H. <i>et al.</i> , "Inhibition of calmodulin-dependent myosin light-chain kinase by growth-hormone-releasing factor and vasoactive intestinal peptide," <i>Biochem. J.</i> , 300:901-905 (1994).
	C62	Smiley, J.D., "Southwestern Internal Medicine Conference: The Many Faces of Scleroderma," <i>American Journal Medical Sciences</i> , 304:319-333 (1992).
	C63	Sreedharan, S.P. <i>et al.</i> , "Human Vasoactive Intestinal Peptide Receptors Expressed By Stable Transfectants Couple To Two Distinct Signaling Pathways," <i>Biochemical Biophysical Research Communications</i> , 203(1):141-148 (August, 1994).
	C64	Stallwood, D. <i>et al.</i> , "Identity of a Membrane-bound Vasoactive Intestinal Peptide-binding Protein with Calmodulin," <i>Journal of Biological Chemistry</i> , 267(27):19617-19621 (September, 1992).
	C65	Stallwood, et al., "Is Calmodulin A Neuropeptide Receptor," <i>FASEB J.</i> 7:1054 (1993)
	C65	Suzuki, H., <i>et al.</i> , "Encapsulation of Vasoactive Intestinal Peptide into Liposomes: Effects on Vasodilation <i>in Vivo</i> ," <i>Life Sciences</i> , 57(15):1451-1457 (1995).
	C67	Suzuki, H. <i>et al.</i> , "Neutral Endopeptidase Modulates VIP-Induced Vasodilation in Hamster Cheek Pouch Vessels <i>In Situ</i> ," <i>Am. J. Physiol.</i> , 271(2 pt. 2):R393-397 (August, 1996).
	C68	Suzuki, H. <i>et al.</i> , "Encapsulation of VIP into Liposomes Restores Vasorelaxation in Hypertension <i>in Situ</i> ," <i>American Journal of Physiology</i> , 271(Heart Circ. Physiol., 40):H282-H287 (1996).
	C69	Theriault, Y. <i>et al.</i> , "Structural Determination of the Vasoactive Intestinal Peptide by Two-Dimensional H-NMR Spectroscopy," <i>Biopolymers</i> , 31:459-464 (1991).
	C70	Torchilin, et al., "Molecular Mechanism of Liposome and Immunoliposome Steric Protection with Poly(Ethylene Glycol): Theoretical and Experimental Proofs of the Role of Polymer Chain Flexibility," <i>Stealth Liposomes</i> pp. 51-62 (1995)
u	C71	Trubetskoy, V.S. <i>et al.</i> , "Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents," <i>Advanced Drug Delivery Reviews</i> , 16:311-320 (1995).

EXAMINER

kru

DATE CONSIDERED


7/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAR 05 2002

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27611/36927Serial No.  
09/995,403Applicant  
Alkan-Onyuksel et al.Filing Date  
11/27/01Group  
1614

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

 RECEIVED  
 APR 11 2003  
 TECH CENTER 1600 2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C72	Trubetskoy, V.S. <i>et al.</i> , "Stable Polymeric Micelles: Lymphangiographic Contrast Media for Gamma Scintigraphy and Magnetic Resonance Imaging," <i>Acad. Radiol.</i> , 3:232-238 (1996).
C73	Trubetskoy, V. <i>et al.</i> , "Micellar Solubilization of Poorly Soluble or Amphiphilic Substances Using Polyoxyethylene-Lipid Conjugates," <i>Proceedings of International Symposium on Controlled Release Bioactive Materials</i> , 22:452-453 (1995).
C74	Watala, C., <i>et al.</i> , "Melittin-Induced Alterations in Dynamic Properties of Human Red Blood Cell Membranes," <i>Chem-Biol. Interactions</i> , 82:135-149 (1992).
C75	Woodle, M.C. <i>et al.</i> , "Versatility in Lipid Compositions Showing Prolonged Circulation with Sterically Stabilized Liposomes," <i>Biochimica et Biophysica Acta</i> , 1105:193-200 (1992).
C76	Woodle, M.C. <i>et al.</i> , "Improved Long Circulating (Stealth <sup>®</sup> ) Liposomes Using Synthetic Lipids," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> , 17:77-78 (1990).
C77	Yokoyama, M. <i>et al.</i> , "Preparation of adriamycin-conjugated poly(ethylene glycol)-poly (aspartic acid) block copolymer," <i>Makromol Chem. Rapid Commun.</i> , 8:431-435 (1987).
C78	Zareie, H.M. <i>et al.</i> , "STM images of PDLLA-PEG copolymer micelles," <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 112:19-24 (1996).
C79	Zorn, N.E. <i>et al.</i> , "Vasoactive Intestinal Peptide (VIP) Activation of Nuclear Protein Kinase C in Purified Nuclei of Rat Splenocytes," <i>Biochemical Pharmacology</i> , 40:2689-2694 (1990).

EXAMINER

khe

DATE CONSIDERED

7/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.